UBS/CALL/IDORSIA/8.008/0.125/20.09.24 Stock

UBS/CALL/IDORSIA/8.008/0.125/20.09.24 Share Price

Warrant

PIDIMU

CH1268671604

Market Closed - Swiss Exchange 08:50:00 19/07/2023 pm IST
0.22 ^CHF	+10.00%

1 month

-35.29%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart IDORSIA LTD

Chart UBS/CALL/IDORSIA/8.008/0.125/20.09.24

Latest news about IDORSIA LTD

Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024	31/05	GL
Idorsia : Invitation to the AGM 2024	23/05	PU
Idorsia : Supplement to the invitation to the AGM 2024	23/05	PU
Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders	23/05	GL

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	IDORSIA LTD
Issuer	UBS
	PIDIMU
ISIN	CH1268671604
Date issued	15/05/2023
Strike	8.008 CHF
Maturity	20/09/2024 (110 Days)
Parity	8 : 1
Emission price	0.33 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.37 CHF
Lowest since issue	0.15 CHF

Company Profile

Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.

Sector

More about the company